Biolegend, 421101, TMB Substrate Set, VO30

The TMB Substrate Set contains 110 ml TMB Substrate A and 110 ml TMB Substrate B, sufficient for twenty 96-well plates. It is formulated with 3, 3', 5, 5' tetramethyl benzidine (TMB). The substrate can be catalyzed with peroxidase to produce a pale blue color which can be read spectrophotometrically at 370 or 620-650 nm. The TMB reaction may be stopped with BioLegend's Stop Solution (Cat. No. 423001), and read at 450 nm.
VO30
Storage & Handling: The TMB Substrate Set (TMB Substrate A and TMB Substrate B) should be stored between 2°C and 8°C. Avoid prolonged exposure to light, contact with metal, air, or extreme temperatures.
Application: ELISA
Recommended Usage: TMB Substrate A should be clear and colorless. TMB Substrate B should be colorless to a very light amber. TMB Substrate is the mixture of equal volumes of TMB Substrate A with TMB Substrate B. For example, for one plate, mix 5.5 ml TMB Substrate A with 5.5 ml of TMB Substrate B in a clean container. Mix immediately before use. After mixing the reagents together, TMB substrate working solution should be colorless or very faint blue.
Application Notes: Warm to room temperature prior to use. To prepare a working solution, mix equal volumes of TMB Substrate A and TMB Substrate B. Prepare only the amount needed for each assay run. After wells are completely washed, to remove unbound antibody and HRP, add 100 µl to 200 µl substrate solution to each well. Discard any remaining working solution after use. For endpoint assays, add 50 µl to 100 µl of Stop Solution (2N H2SO4 or 1M H3PO4), which changes the color from blue to yellow. Read at 450 nm (minus 570 nm for wavelength correction) within 30 minutes of stopping the reaction. For kinetic assays, read the blue color at 620 - 650 nm.
Application References(PubMed link indicates BioLegend citation): Kim MS, et al. 2008. J Biochem. 143:497. PubMed McNally A, et al. 2011. PNAS. 108:7529. PubMed Santiago FW, et al. 2012. Vaccine. 30:4606. PubMed Wan LY, et al. 2014. Toxicol Sci. PubMed de Pablo P, et al. 2014. Ann Rheum Dis. 73:580. PubMed
Product Citations: Kordyukova L, et al. 2023. Viruses. 15:. PubMed Yu M, et al. 2023. Nat Commun. 14:2164. PubMed Silva-Cayetano A, et al. 2023. Nat Immunol. . PubMed Lorenz P, et al. 2023. Front Immunol. 14:1192395. PubMed Nishimagi A, et al. 2023. Clin Exp Med. . PubMed Hellgren F, et al. 2023. Nat Commun. 14:3713. PubMed Sakamoto A, et al. 2022. Vaccines (Basel). 10: . PubMed Connelly GG, et al. 2022. Cell Rep Methods. 2:100273. PubMed Lu S, et al. 2023. Nat Commun. 14:17. PubMed Barajas-Mora EM, et al. 2023. Nat Immunol. 24:320. PubMed Gurram RK, et al. 2023. Cell Rep. 42:112073. PubMed Jameie F, et al. 2021. Iran J Parasitol. 1:16. PubMed Vanderleyden I, et al. 2020. Cell Rep. 30:611. PubMed Wenzek C, et al. 2022. iScience. 25:105540. PubMed Bryant JD, et al. 2021. Brain Behav Immun. 97:204. PubMed Jameie F, et al. 2020. Arch Razi Inst. 75:327. PubMed Liu W, et al. 2016. J Virol. 90: 8496 - 8508. PubMed Hsiue EH, et al. 2021. Science. 371:. PubMed Peng L, et al. 2022. Cell Rep. 40:111160. PubMed Brooks JF, et al. 2020. J Immunol. 205:1239. PubMed Fertey J, et al. 2021. Methods Mol Biol. 2414:97. PubMed He Y, et al. 2021. Bio Protoc. 11:e3905. PubMed Brooks JF, et al. 2020. Cytotherapy. 22:436. PubMed Stebegg M, et al. 2019. Nat Commun. 2.113194444. PubMed Lee JL, et al. 2022. Aging Cell. 21:e13692. PubMed Alapati T, et al. 2021. Genes (Basel). 13:. PubMed Chang JH, et al. 2022. Vaccines (Basel). 10:. PubMed Sari AN, et al. 2022. Cancers (Basel). 14:. PubMed Walczewska M, et al. 2017. Adv Exp Med Biol. 10.1007/978-94-024-1079-2_41. PubMed Sen K, et al. 2021. Front Immunol. 12:733539. PubMed Han JP, et al. 2022. Sci Adv. 8:eabj6901. PubMed Ding P, et al. 2022. Cell Rep. 39:110851. PubMed Wu J, et al. 2020. Immunity. 53:115. PubMed Malik V, et al. 2020. Int J Mol Sci. 21:00. PubMed Ramos-Pinto L, et al. 2021. Animals (Basel). 11:. PubMed Nuvolone M, et al. 2017. PLoS One. 12:e0171923. PubMed Qi T, et al. 2020. Cell Rep. 33:108452. PubMed Oh E, et al. 2018. Front Oncol. 0.716666667. PubMed Schwaderer J, et al. 2020. Cell Death Dis. 11:154. PubMed Debernardi S, et al. 2020. PLoS Med. 17:e1003489. PubMed Morgan S, et al. 2016. J Immunol. 196: 5014 - 5023. PubMed Younis RH, et al. 2021. Front Immunol. 596646:12. PubMed Fang Z, et al. 2022. Nat Commun. 13:3250. PubMed Groeneveld D, et al. 2020. J Hepatol. 72:146. PubMed Nogales A, et al. 2017. Virology. 500:1-10. PubMed Wan L, et al. 2014. Toxicol Sci. 139:83. PubMed Pagan JD, et al. 2018. Cell. 172:564. PubMed Del Alcazar D, et al. 2019. Cell Rep. 28:3047. PubMed Peng L, et al. 2022. Cell Rep Med. 3:100634. PubMed Sun L, et al. 2021. Sci Rep. 11:12477. PubMed Wu J, et al. 2021. Nat Cell Biol. 23:75. PubMed Uematsu T, et al. 2016. Sci Rep. 6:37815. PubMed Yang K, et al. 2020. Cell Chem Biol. 27:866. PubMed Garg S, et al. 2019. Biotechniques. 67:166. PubMed Falck-Jones S, et al. 2021. J Clin Invest. 131: . PubMed Vijver SV, et al. 2021. Front Immunol. 12:733561. PubMed Barbier M, et al. 2022. Front Immunol. 13:948431. PubMed Surawut S, et al. 2017. Sci Rep. 7:40006. PubMed McNally A, et al. 2011. Proc Natl Acad Sci U S A. 108:7529. PubMed Kim M, et al. 2008. J Biochem. 143:497. PubMed Strazza M, et al. 2022. Mol Ther Methods Clin Dev. 27:380. PubMed Pedicone C, et al. 2022. iScience. 25:104170. PubMed Phan TS, et al. 2021. Sci Adv. 7:. PubMed Salehi S, et al. 2017. PLoS One. 10.1371/journal.pone.0163614. PubMed Miller H, et al. 2021. J Clin Microbiol. 59:e0096421. PubMed Leppkes M, et al. 2020. EBioMedicine. 58:102925. PubMed Parrish H, et al. 2016. Proc Natl Acad Sci U S A. 113: 3000 - 3005. PubMed Pablo P, et al. 2014. Ann Rheum Dis. 73:580. PubMed Guo Y, et al. 2021. Nat Commun. 12:2623. PubMed Reis B, et al. 2021. Mar Drugs. 19:. PubMed Knopf J, et al. 2022. Cells. 11:. PubMed Yang E, et al. 2015. Acta Biochim Biophys Sin. 47: 588-596. PubMed Santiago F, et al. 2012. Vaccine. 30:4606. PubMed Lee KS, et al. 2022. iScience. 25:105038. PubMed Yang K, et al. 2021. STAR Protoc. 2:100288. PubMed
RRID: SCR_001134 (BioLegend Cat. No. 421101)
Gene ID: NA
Regulatory Status: RUO
Other Names: TMB Substrate
Q: What is the difference between your two substrate solutions: TMB Substrate Reagent Set (Cat. No. 421101) and TMB High Sensitivity Substrate Solution (Cat. No. 421501)?
A: TMB Substrate Reagent Set (Cat. No. 421101) contains two components, which need to be mixed immediately prior to use. The TMB High Sensitivity Substrate Solution (Cat. No. 421501) contains everything in one solution with special stabilizers. It is a high kinetic substrate solution which generally gives higher signal. The type of substrate used for an assay can affect the optical density (OD) achievable and the time required to achieve the desired OD.